Cancer clinical trials in the region Île-de-France
787 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lung cancer
#NCT07563738
#2025-524620-22-00
Partie 2 - Cohorte Sotorasib, CBNPC prétraités
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Orion Pharma
Phase 1 / Phase 2
Lung cancer
#NCT07563738
#2025-524620-22-00
Partie 2 - Cohorte Sotorasib, CBNPC naïfs de traitement
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
4 recruiting sites
Orion Pharma
Phase 1 / Phase 2
Lung cancer
Stomach and esophageal cancer
Head and neck cancer
Cervical / Vulvar / Vaginal cancer
#NCT06747585
#2024-515459-39-00
Phase I d'expansion de dose monothérapie et phase 2 monothérapie
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Cervical cancer
Required histologic sub types
Squamous NSCLC
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Lung cancer
Stomach and esophageal cancer
Head and neck cancer
Cervical / Vulvar / Vaginal cancer
#NCT06747585
#2024-515459-39-00
Phase I d'escalade de dose
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Cervical cancer
Required histologic sub types
Squamous NSCLC
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Lung cancer
Stomach and esophageal cancer
Head and neck cancer
Cervical / Vulvar / Vaginal cancer
#NCT06747585
#2024-515459-39-00
Phase I d'expansion de dose combinaison
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Cervical cancer
Required histologic sub types
Squamous NSCLC
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Prostate cancer
#NCT07332455
#2025-523874-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
2 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2
Breast cancer
#NCT07100106
#2025-521128-31-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
4 recruiting sites
Genentech, Inc
Phase 1 / Phase 2
Colon cancer
Rectal cancer
#NCT03526835
#2017-004745-24
Cohortes en combinaison mCRC
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
Other KRAS
BRAF
HRAS
KRAS G12C
KRAS G12D
KRAS non G12C
NRAS
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
Merus
Phase 1 / Phase 2
Kidney cancer
#NCT07293351
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
1 recruiting site
Bristol-Myers Squibb
Phase 1 / Phase 2
Kidney cancer
#NCT07293351
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
1 recruiting site
Bristol-Myers Squibb